ACIP Recommends Use of Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born ...

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Clesrovimab is a monoclonal antibody (mAb) that protects against RSV subtypes A and B. Merck investigators presented the results of two phase 2b/3 trials at IDWeek in October.

Clesrovimab is a monoclonal antibody that is given as a shot to babies 8 months or younger who are born during or entering their first RSV season. The RSV season generally spans from October to March.

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...